2-chlorofuro[2,3-c]pyridin-7-amine | 1326713-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: 2-chlorofuro[2,3-c]pyridin-7-amine
• CAS: 1326713-69-2
• 化学式: C₇H₅ClN₂O
• 分子量: 168.583
• InChiKey: WSKBUDGIDZNKGB-UHFFFAOYSA-N

物化性质

• 沸点：
  323.1±37.0 °C(Predicted)
• 密度：
  1.481±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chlorofuro[2,3-c]pyridin-7-amine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-碘代丁二酰亚胺 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 生成 1-{4-[4-(7-amino-2-chlorofuro[2,3-c]pyridin-4-yl)-1H-pyrazol-1-yl]piperidin-1-yl}ethanone
  参考文献：
  名称：

  Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1

  摘要：

  The discovery and potency optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. Micromolar hits taken from high-throughput screening were optimized for biochemical and cellular mechanistic potency to similar to 10 nM, as exemplified by compound 12az. Application of structure-based drug design aided by co-crystal structures of TAK1 with inhibitors significantly shortened the number of iterations required for the optimization. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.053
• 作为产物：
  描述：

  呋喃并[2,3-c]吡啶-7(6h)-酮 在 盐酸 、 4-二甲氨基吡啶 、 溶剂黄146 、 锌 、 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 正丁醇 为溶剂， 生成 2-chlorofuro[2,3-c]pyridin-7-amine
  参考文献：
  名称：

  Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1

  摘要：

  The discovery and potency optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. Micromolar hits taken from high-throughput screening were optimized for biochemical and cellular mechanistic potency to similar to 10 nM, as exemplified by compound 12az. Application of structure-based drug design aided by co-crystal structures of TAK1 with inhibitors significantly shortened the number of iterations required for the optimization. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.053

文献信息

• 7-AMINOFUROPYRIDINE DERIVATIVES
  申请人：Hornberger Keith R.

  公开号：US20120046267A1

  公开（公告）日：2012-02-23

  Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

  公式1的化合物，如下所示并在此定义：其药学上可接受的盐，合成方法，中间体，配方以及使用它们进行疾病治疗的方法，包括治疗癌症，例如由TAK1至少部分驱动的肿瘤或适当的TAK1抑制剂有效的肿瘤。本摘要不限于该发明。
• 7-aminofuropyridine derivatives
  申请人：Hornberger Keith R.

  公开号：US08378104B2

  公开（公告）日：2013-02-19

  Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

  本发明涉及公式1的化合物，如下所示并在此定义：其药学上可接受的盐，合成方法，中间体，制剂以及使用其进行疾病治疗的方法，包括治疗癌症，例如由TAK1驱动或适用于TAK1抑制剂有效的肿瘤。本摘要不限制本发明。
• [EN] 7-AMINOFUROPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA 7-AMINOFUROPYRIDINE
  申请人：OSI PHARMACEUTICALS LLC

  公开号：WO2011100502A8

  公开（公告）日：2011-09-22
• Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics
  作者：Keith R. Hornberger、Xin Chen、Andrew P. Crew、Andrew Kleinberg、Lifu Ma、Mark J. Mulvihill、Jing Wang、Victoria L. Wilde、Mark Albertella、Mark Bittner、Andrew Cooke、Salam Kadhim、Jennifer Kahler、Paul Maresca、Earl May、Peter Meyn、Darlene Romashko、Brianna Tokar、Roy Turton

  DOI：10.1016/j.bmcl.2013.06.054

  日期：2013.8

  The kinase selectivity and pharmacokinetic optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. The intersection of insights from molecular modeling, computational prediction of metabolic sites, and in vitro metabolite identification studies resulted in a simple and unique solution to both of these problems. These efforts culminated in the discovery of compound 13a, a potent, relatively selective inhibitor of TAK1 with good pharmacokinetic properties in mice, which was active in an in vivo model of ovarian cancer. (c) 2013 Elsevier Ltd. All rights reserved.
• US8378104B2
  申请人：——

  公开号：US8378104B2

  公开（公告）日：2013-02-19